Singapore-based healthcare services group Zuellig Pharma has acquired the Zam-Buk and Vapex consumer healthcare brands from Bayer Consumer Care for Thailand, Singapore, Indonesia, Malaysia, and Brunei.

Zam-Buk is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. Launched in 1902, the product has become a household brand. Vapex is a nasal inhaler used to help relieve nasal congestion. Introduced in 1917, the brand has gained widespread recognition, particularly in Thailand.

The acquisition of the two brands is part of Zuellig Pharma's efforts to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company's second consumer healthcare acquisition, following Propan in the Philippines.

John Graham, chief executive officer of Zuellig Pharma, comments: "Zam-Buk and Vapex are enduring brands with deep heritage and trust in the communities they serve. By combining the brands' legacy with Zuellig Pharma's regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region. In doing so, these brands will continue to remain relevant, easy to find, and accessible to consumers."